APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gastro Esophageal Reflux Disease (GERD) Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gastro Esophageal Reflux Disease (GERD) Drug Market Outlook and Growth Opportunities 2026

26 December 2025196 pages

Choose your research edition.

Industry ResearchGastro Esophageal Reflux Disease (GERD) Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Gastro Esophageal Reflux Disease (GERD) Drug Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Gastro Esophageal Reflux Disease (GERD) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gastro Esophageal Reflux Disease (GERD) Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Gastro Esophageal Reflux Disease (GERD) Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Gastro Esophageal Reflux Disease (GERD) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gastro Esophageal Reflux Disease (GERD) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gastro Esophageal Reflux Disease (GERD) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gastro Esophageal Reflux Disease (GERD) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gastro Esophageal Reflux Disease (GERD) Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gastro Esophageal Reflux Disease (GERD) Drug market include Addex Therapeutics, Aros Pharma, AstraZeneca, Plc., Medtronic, Takeda Pharmaceutical Company Limited, The Kroger Co., GlaxoSmithKline, Pfizer and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gastro Esophageal Reflux Disease (GERD) Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gastro Esophageal Reflux Disease (GERD) Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gastro Esophageal Reflux Disease (GERD) Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gastro Esophageal Reflux Disease (GERD) Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Gastro Esophageal Reflux Disease (GERD) Drug Segment by Company

Addex Therapeutics

Aros Pharma

AstraZeneca, Plc.

Medtronic

Takeda Pharmaceutical Company Limited

The Kroger Co.

GlaxoSmithKline

Pfizer

Merck

Novartis AG

Gastro Esophageal Reflux Disease (GERD) Drug Segment by Type

H2 Receptor Antagonist

Proton Pump Inhibitor (PPi)

Antacids

Gastro Esophageal Reflux Disease (GERD) Drug Segment by Application

Clinic

Hospital

Medical Center

Others

Gastro Esophageal Reflux Disease (GERD) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Gastro Esophageal Reflux Disease (GERD) Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gastro Esophageal Reflux Disease (GERD) Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gastro Esophageal Reflux Disease (GERD) Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Gastro Esophageal Reflux Disease (GERD) Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastro Esophageal Reflux Disease (GERD) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gastro Esophageal Reflux Disease (GERD) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastro Esophageal Reflux Disease (GERD) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gastro Esophageal Reflux Disease (GERD) Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gastro Esophageal Reflux Disease (GERD) Drug industry.

Chapter 3: Detailed analysis of Gastro Esophageal Reflux Disease (GERD) Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gastro Esophageal Reflux Disease (GERD) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gastro Esophageal Reflux Disease (GERD) Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gastro Esophageal Reflux Disease (GERD) Drug Industry Trends Table 2. Gastro Esophageal Reflux Disease (GERD) Drug Industry Drivers Table 3. Gastro Esophageal Reflux Disease (GERD) Drug Industry Opportunities and Challenges Table 4. Gastro Esophageal Reflux Disease (GERD) Drug Industry Restraints Table 5. Global Gastro Esophageal Reflux Disease (GERD) Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gastro Esophageal Reflux Disease (GERD) Drug Revenue Share by Company (2021-2026) Table 7. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Company (2021-2026) Table 9. Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Gastro Esophageal Reflux Disease (GERD) Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gastro Esophageal Reflux Disease (GERD) Drug Key Company Manufacturing Base & Headquarters Table 12. Global Gastro Esophageal Reflux Disease (GERD) Drug Company, Product Type & Application Table 13. Global Gastro Esophageal Reflux Disease (GERD) Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gastro Esophageal Reflux Disease (GERD) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of H2 Receptor Antagonist Table 18. Significant Companies of Proton Pump Inhibitor (PPi) Table 19. Significant Companies of Antacids Table 20. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Type (2021-2026) Table 24. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Type (2027-2032) Table 25. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type (2021-2026) Table 29. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Clinic Table 31. Significant Companies of Hospital Table 32. Significant Companies of Medical Center Table 33. Significant Companies of Others Table 34. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Application (2021-2026) Table 38. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Application (2027-2032) Table 39. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application (2021-2026) Table 43. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application (2027-2032) Table 44. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Market Share by Region (2021-2026) Table 47. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region (2027-2032) & (K Units) Table 48. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Market Share by Region (2027-2032) Table 49. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Region (2021-2026) Table 52. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Region (2027-2032) Table 54. Global Gastro Esophageal Reflux Disease (GERD) Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Gastro Esophageal Reflux Disease (GERD) Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2021-2026) & (K Units) Table 59. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Market Share by Country (2021-2026) Table 60. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Market Share by Country (2027-2032) Table 62. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Market Share by Country (2027-2032) Table 66. Addex Therapeutics Company Information Table 67. Addex Therapeutics Business Overview Table 68. Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 70. Addex Therapeutics Recent Development Table 71. Aros Pharma Company Information Table 72. Aros Pharma Business Overview Table 73. Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 75. Aros Pharma Recent Development Table 76. AstraZeneca, Plc. Company Information Table 77. AstraZeneca, Plc. Business Overview Table 78. AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 80. AstraZeneca, Plc. Recent Development Table 81. Medtronic Company Information Table 82. Medtronic Business Overview Table 83. Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 85. Medtronic Recent Development Table 86. Takeda Pharmaceutical Company Limited Company Information Table 87. Takeda Pharmaceutical Company Limited Business Overview Table 88. Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 90. Takeda Pharmaceutical Company Limited Recent Development Table 91. The Kroger Co. Company Information Table 92. The Kroger Co. Business Overview Table 93. The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 95. The Kroger Co. Recent Development Table 96. GlaxoSmithKline Company Information Table 97. GlaxoSmithKline Business Overview Table 98. GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 100. GlaxoSmithKline Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 105. Pfizer Recent Development Table 106. Merck Company Information Table 107. Merck Business Overview Table 108. Merck Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Merck Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 110. Merck Recent Development Table 111. Novartis AG Company Information Table 112. Novartis AG Business Overview Table 113. Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio Table 115. Novartis AG Recent Development Table 116. Key Raw Materials Table 117. Raw Materials Key Suppliers Table 118. Gastro Esophageal Reflux Disease (GERD) Drug Distributors List Table 119. Gastro Esophageal Reflux Disease (GERD) Drug Customers List Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Gastro Esophageal Reflux Disease (GERD) Drug Product Image Figure 2. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales (2021-2032) & (K Units) Figure 5. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Gastro Esophageal Reflux Disease (GERD) Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. H2 Receptor Antagonist Image Figure 10. Proton Pump Inhibitor (PPi) Image Figure 11. Antacids Image Figure 12. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type (2021-2032) Figure 18. Clinic Image Figure 19. Hospital Image Figure 20. Medical Center Image Figure 21. Others Image Figure 22. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application (2021-2032) Figure 28. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Gastro Esophageal Reflux Disease (GERD) Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Gastro Esophageal Reflux Disease (GERD) Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • H2 Receptor Antagonist
  • Proton Pump Inhibitor (PPi)
  • Antacids
Applications
  • Clinic
  • Hospital
  • Medical Center
  • Others
Companies covered
  • Addex Therapeutics
  • Aros Pharma
  • AstraZeneca, Plc.
  • Medtronic
  • Takeda Pharmaceutical Company Limited
  • The Kroger Co.
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032)
  4. 1.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gastro Esophageal Reflux Disease (GERD) Drug Market Dynamics
  1. 2.1 Gastro Esophageal Reflux Disease (GERD) Drug Industry Trends
  2. 2.2 Gastro Esophageal Reflux Disease (GERD) Drug Industry Drivers
  3. 2.3 Gastro Esophageal Reflux Disease (GERD) Drug Industry Opportunities and Challenges
  4. 2.4 Gastro Esophageal Reflux Disease (GERD) Drug Industry Restraints
3 Gastro Esophageal Reflux Disease (GERD) Drug Market by Company
  1. 3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Revenue Ranking in 2025
  2. 3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Revenue by Company (2021-2026)
  3. 3.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Gastro Esophageal Reflux Disease (GERD) Drug Average Price by Company (2021-2026)
  5. 3.5 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Ranking (2024-2026)
  6. 3.6 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Product Type and Application
  8. 3.8 Global Gastro Esophageal Reflux Disease (GERD) Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gastro Esophageal Reflux Disease (GERD) Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gastro Esophageal Reflux Disease (GERD) Drug Market by Type
  1. 4.1 Gastro Esophageal Reflux Disease (GERD) Drug Type Introduction
  2. 4.1.1 H2 Receptor Antagonist
  3. 4.1.2 Proton Pump Inhibitor (PPi)
  4. 4.1.3 Antacids
  5. 4.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type
  6. 4.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type
  10. 4.3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type (2021-2032)
5 Gastro Esophageal Reflux Disease (GERD) Drug Market by Application
  1. 5.1 Gastro Esophageal Reflux Disease (GERD) Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Medical Center
  5. 5.1.4 Others
  6. 5.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application
  7. 5.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application
  11. 5.3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Application (2021-2032)
  13. 5.3.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application (2021-2032)
6 Gastro Esophageal Reflux Disease (GERD) Drug Regional Sales and Value Analysis
  1. 6.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Region (2027-2032)
  5. 6.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Gastro Esophageal Reflux Disease (GERD) Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032)
  12. 6.6.2 North America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032)
  21. 6.9.2 South America Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Country, 2025 VS 2032
7 Gastro Esophageal Reflux Disease (GERD) Drug Country-level Sales and Value Analysis
  1. 7.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales by Country (2027-2032)
  6. 7.4 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gastro Esophageal Reflux Disease (GERD) Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gastro Esophageal Reflux Disease (GERD) Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Addex Therapeutics
  2. 8.1.1 Addex Therapeutics Company Information
  3. 8.1.2 Addex Therapeutics Business Overview
  4. 8.1.3 Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Addex Therapeutics Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  6. 8.1.5 Addex Therapeutics Recent Developments
  7. 8.2 Aros Pharma
  8. 8.2.1 Aros Pharma Company Information
  9. 8.2.2 Aros Pharma Business Overview
  10. 8.2.3 Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aros Pharma Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  12. 8.2.5 Aros Pharma Recent Developments
  13. 8.3 AstraZeneca, Plc.
  14. 8.3.1 AstraZeneca, Plc. Company Information
  15. 8.3.2 AstraZeneca, Plc. Business Overview
  16. 8.3.3 AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca, Plc. Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  18. 8.3.5 AstraZeneca, Plc. Recent Developments
  19. 8.4 Medtronic
  20. 8.4.1 Medtronic Company Information
  21. 8.4.2 Medtronic Business Overview
  22. 8.4.3 Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Medtronic Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  24. 8.4.5 Medtronic Recent Developments
  25. 8.5 Takeda Pharmaceutical Company Limited
  26. 8.5.1 Takeda Pharmaceutical Company Limited Company Information
  27. 8.5.2 Takeda Pharmaceutical Company Limited Business Overview
  28. 8.5.3 Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Takeda Pharmaceutical Company Limited Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  30. 8.5.5 Takeda Pharmaceutical Company Limited Recent Developments
  31. 8.6 The Kroger Co.
  32. 8.6.1 The Kroger Co. Company Information
  33. 8.6.2 The Kroger Co. Business Overview
  34. 8.6.3 The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 The Kroger Co. Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  36. 8.6.5 The Kroger Co. Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Novartis AG
  56. 8.10.1 Novartis AG Company Information
  57. 8.10.2 Novartis AG Business Overview
  58. 8.10.3 Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novartis AG Gastro Esophageal Reflux Disease (GERD) Drug Product Portfolio
  60. 8.10.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gastro Esophageal Reflux Disease (GERD) Drug Value Chain Analysis
  2. 9.1.1 Gastro Esophageal Reflux Disease (GERD) Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gastro Esophageal Reflux Disease (GERD) Drug Sales Mode & Process
  6. 9.2 Gastro Esophageal Reflux Disease (GERD) Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gastro Esophageal Reflux Disease (GERD) Drug Distributors
  9. 9.2.3 Gastro Esophageal Reflux Disease (GERD) Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst